Skip to main content
SpringerLink
Log in

Selection of Zidovudine-Resistant Variants of Human Immunodeficiency Virus by Therapy

  • Chapter
Genetic Diversity of RNA Viruses

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 176))

Abstract

The likelihood of emergence of drug resistance is a function of mutation rate and the number of replicative events. The mutation rate of human immunodeficiency virus (HIV) is presumed to be at least as high as any virus with a single-stranded RNA genome. The number of replicative events in a host infected with HIV are incalculably high as a result of years of persistent replication that is poorly restricted by immune surveillance. Viral chemotherapy in humans has selected for drug-resistant variants of influenza A virus, herpes simplex virus, varicella zoster virus, cytomegalovirus and rhinovirus (Richman 1990). The prospect of drug resistance to zidovudine (AZT) therefore did not appear as a surprise to many.

This work was supported by grants HB-67019, Al-27670, Al-30457, Al-29164 from the National Institutes of Health and by the Research Center for AIDS and HIV Infection of the San Diego Veterans Affairs Medical Center

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Boucher CAB, Tersmette M, Lange JMA, Kellam P, de Goede REY, Mulder JW, Darby G, Goudsmit J, Larder BA (1990) Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 336: 585–590.

    Article  PubMed  CAS  Google Scholar 

  • Bozzette SA, Richman DD (1990) Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of AZT and ddC. Am J Med [Suppl 5B] 88: 24S - 26S

    Article  CAS  Google Scholar 

  • Carpenter CCJ et al. (1990) State-of-the-art conference on azidothymidine therapy for early HIV infection. Am J Med 89: 335–344

    Article  Google Scholar 

  • Chesebro B, Wehrly K (1988) Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol 62: 3779–3788

    PubMed  CAS  Google Scholar 

  • Fischi MA, Parker CB, Pettinelli C, Wulfsohn M, Hirsch MS, Collier AC, Antoniskis D, Ho M, Richman DD, Fuchs E, Merigan TC, Reichman RC, Gold J, Steigbigel N, Leoung GS, Rasheed S, Tsiatis A, AIDS Clinical Trials Group (1990) A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 323: 1009–1014

    Article  Google Scholar 

  • Furman PH, Fyfe JA, St Clair MH, Weinhold KJ, Rideout JL, Nusinoff-Lehrman S, Bolognesi DP, Broder S, Mitsuya H, Barry DW (1986) Phosphorylation of 3’-azido-3’deoxythymidine and selective interaction of the 5’-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83: 8333–8337

    Article  PubMed  CAS  Google Scholar 

  • Guatelli JC, Whitfield KM, Kwoh DY, Barringer KJ, Richman DD, Gingeras TR (1990) Isothermal, in vitro amplification of nucleic acids by a multi enzyme reaction modeled after retroviral replication. Proc Natl Acad Sci USA 87: 1874–1878

    Article  PubMed  CAS  Google Scholar 

  • Gingeras TR, Prodanovich P, Latimer T, Guatelli JC, Richman DD, Barringer KJ (1991) Use of self-sustained sequence replication (35R) amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus. J Infect Dis (in press)

    Google Scholar 

  • Land S, Treloar T, McPhee D, Birch C, Doherty R, Cooper D, Gust ID (1990) Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J Infect Dis 161: 326–329

    Article  PubMed  CAS  Google Scholar 

  • Larder BA, Kemp SD (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155–1158

    Article  PubMed  CAS  Google Scholar 

  • Larder BA, Darby G, Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731–1734

    Article  PubMed  CAS  Google Scholar 

  • Larder BA, Chesebro B, Richman DD (1990) Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 34: 436–441

    PubMed  CAS  Google Scholar 

  • López-Galindez C, Rojas JM, Nâjera R, Richman DD, Perucho M (1991) Characterization of genetic variation and AZT resistance mutations of HIV by the RNAs A mismatch cleavage method. Proc Natl Acad Sci USA 88: 4280–4284

    Article  PubMed  Google Scholar 

  • Meng TC, Fisch) MA, Richman DD (1990) ACTG 106: phase I/II study of ddC and AZT: combination in patients with AIDS and advanced ARC. Am J Med [Suppl 5B] 88: 27S - 30S

    Article  CAS  Google Scholar 

  • Remington KM, Chesebro B, Wehrly K, Pedersen NC, North TW (1991) Mutants of feline immunodeficiency virus resistant to 3’-azido-3’-deoxythymidine. J Virol 65: 308–312

    PubMed  CAS  Google Scholar 

  • Richman DD (1990) Viral drug resistance. Curr Opin Infect Dis 3: 819–823

    Article  Google Scholar 

  • Richman DD, Grimes JM, Lagakos SW (1990) Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J AIDS 3: 743–746

    CAS  Google Scholar 

  • Richman DD, Rosenthal AS, Skoog M, Eckner RJ, Chou T-C, Sabo JP, Merluzzi VJ (1991a) BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 35: 305–308

    PubMed  CAS  Google Scholar 

  • Richman DD, Guatelli JC, Grimes J, Tsiatis A, Gingeras TR (1991b) The detection of mutations associated with zidovudine resistance in human immunodeficiency virus utilizing the polymerase chain reaction. J Infect Dis (in press)

    Google Scholar 

  • Rooke R, Tremblay M, Soudeyns H, DeStephano L, Yao X-J, Fanning M, Montaner JSF, O’Shaughnessy M, Gelmon K, Tsoukas CD, Gill J, Ruedy J, Wainberg MA, Canadian Zidovudine Multi-Centre Study Group (1989) Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 3: 411–415

    Article  PubMed  CAS  Google Scholar 

  • Skowron G, Merigan TC (1990) Alternating and intermittent regimens of zidovudine (3’-azido-3’deoxythymidine) and dideoxycytidine (2’,3’-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Am J Med [Suppl 5B ) 88: 20S - 23S

    Article  Google Scholar 

  • Smith MS, Brian EL, Pagano JS (1987) Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine. J Virol 61: 3769–3773

    PubMed  CAS  Google Scholar 

  • Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour DH, Reichman RC, Bartlett JA, Hirsch MS, Murphy RL, Hardy WD, Soiero R, Fisch) MA, Bartlett JG, Merigan TC, Hyslop NE, Richman DD, Valentine FT, Corey L, AIDS Clinical Trials Group (1990) Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 322: 941–949

    Article  PubMed  CAS  Google Scholar 

  • Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain JP, Wills RJ, McAtee N, Fischi MA, Dubinsky R, McNeely MC, Mitsuya H, Pluda JM, Lawley TJ, Leuther MD, Safai B, Collins JM, Myers CE, Broder S (1988) Phase studies of 2’,3’-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1: 76–81

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pathology and Medicine, University of California San Diego and VA Medical Center, Infectious Diseases-111F, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA

    D. D. Richman

Authors
  1. D. D. Richman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biology, C-016, University of California, 92093, San Diego, La Jolla, CA, USA

    John J. Holland Ph.D. (Professor of Biology and Molecular Genetics) (Professor of Biology and Molecular Genetics)

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Richman, D.D. (1992). Selection of Zidovudine-Resistant Variants of Human Immunodeficiency Virus by Therapy. In: Holland, J.J. (eds) Genetic Diversity of RNA Viruses. Current Topics in Microbiology and Immunology, vol 176. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77011-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77011-1_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77013-5

  • Online ISBN: 978-3-642-77011-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation